Stoke Therapeutics Appoints Ian Smith to its Board of Directors
21 9월 2023 - 5:30AM
Business Wire
– Mr. Smith brings significant experience in
the successful development and commercialization of medicines for
rare genetic diseases –
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced the appointment of Ian Smith to its Board of Directors
effective September 19.
“Ian brings more than two decades of significant executive
management experience in the life sciences industry, with a strong
track record of successfully building valuable biotech businesses,”
said Edward M. Kaye, M.D., Chief Executive Officer of Stoke
Therapeutics. “His diverse experience in developing
disease-modifying medicines for severe genetic diseases along with
his deep strategic, operating and financial expertise will make him
an integral resource for the Stoke team, especially as we work to
advance STK-001 for Dravet syndrome into a Phase 3 program and
build a global organization.”
“Stoke’s approach to targeting the underlying cause of severe
diseases by upregulating protein expression represents a unique
opportunity to develop first-in-class disease-modifying new
medicines for many diseases that have been challenging to treat
with existing approaches,” said Mr. Smith. “I am pleased to join
Stoke’s Board of Directors and look forward to working with the
team to help them achieve their goals. Together, I believe we have
the opportunity to fundamentally change the way certain diseases
are treated, starting with Dravet syndrome.”
Ian F. Smith is a director of Stoke Therapeutics. He serves as a
Senior Advisor to Bain Capital Life Sciences since January 2021.
Mr. Smith also serves as Executive Chair of the Board of Directors
of Solid Biosciences (Nasdaq: SLDB), as a director of Foghorn
Therapeutics (Nasdaq: FHTX), Alkeus Pharmaceuticals and iVexSol
Inc, and formerly as a director and Executive Chair of the board of
ViaCyte, Inc. (acquired September 2022). Between 2001 and 2019, Mr.
Smith served as Executive Vice President and Chief Operating
Officer, and Chief Financial Officer at Vertex Pharmaceuticals. He
holds a B.A. with honors in accounting and finance from Manchester
Metropolitan University (UK).
About Stoke Therapeutics Stoke Therapeutics (Nasdaq:
STOK), is a biotechnology company dedicated to addressing the
underlying cause of severe diseases by upregulating protein
expression with RNA-based medicines. Using Stoke’s proprietary
TANGO (Targeted Augmentation of Nuclear Gene Output) approach,
Stoke is developing antisense oligonucleotides (ASOs) to
selectively restore protein levels. Stoke’s first compound,
STK-001, is in clinical testing for the treatment of Dravet
syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/ or follow
Stoke on X @StokeTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230920353156/en/
Stoke Media & Investor Contacts: Dawn Kalmar Chief
Communications Officer dkalmar@stoketherapeutics.com
781-303-8302
Eric Rojas Vice President, Investor Relations
IR@stoketherapeutics.com 617-312-2754
Stoke Therapeutics (NASDAQ:STOK)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Stoke Therapeutics (NASDAQ:STOK)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024